U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT07574489) titled 'Whole Versus Partial Gland Boost During Prostate SBRT' on April 30.
Brief Summary: This phase 2/3 randomized trial evaluates whether dose escalation to the dominant intra-prostatic lesion (DIL) compared to whole gland dose escalation during prostate stereotactic body radiotherapy (SBRT) results in differences in genitourinary (GU) and gastrointestinal (GI) toxicities.
Study Start Date: July 25
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer
Prostate Adenocarcinoma
Intervention:
RADIATION: Prostate stereotactic body radiotherapy with whole gland boost
External beam radiation therapy delivered via linear accelerator-based S...